XON7 / Xenothera - LARVOL DELTA

XON7, a new emerging multitarget immunotherapy against metastatic soft tissue sarcomas (AACR 2025) - "While surgery and radiotherapy are effective for localized disease, advanced and metastatic STS have poor outcomes due to limited efficacy of standard treatments like doxorubicin and frequent therapeutic resistance. XON7 characterized by its plurality of action and potent antitumor efficacy, currently under clinical evaluation, XON7 emerges as a promising immunotherapy for soft tissue sarcomas."

Metastases • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CASP8 • CASP9

XON7, a new Glyco-Humanized Polyclonal Antibody, first in class immunotherapy against several solid tumors (AACR 2024) - "Based on its safe toxicity profile and potent activity, XON7 appeared as a novel and promising cancer immunotherapy to fight against recurrent solid tumor, it is now aimed to reach clinical development, FIH in patients is planned to start before the end of 2023."

Breast Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Osteosarcoma • Prostate Cancer • Sarcoma • Solid Tumor

Suppression of triple-negative breast cancer metastasis by a new glyco-humanized polyclonal antibody (AACR 2025) - "Here, we assess the efficacy of XON7, a first-in-class glyco-humanized polyclonal antibody (GH-pAb), in preclinical models of TNBC. The anti-tumor efficacy of XON7 was assessed in TNBC cell lines for its capacity to induce complement-dependent cytotoxicity (CDC) and apoptosis, compared to paclitaxel and the ADC Sacituzumab Govitecan. XON7 is a multi-target antibody currently under clinical evaluation, it represents a promising candidate for advancing treatment paradigms in TNBC."

Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CASP8 • CASP9

XON27, a novel and potent immunotherapy against hematologic malignancies (AACR 2024) - "The cytotoxicity induced by XON27 in the KMS-12-BM was significantly more potent compared to daratumumab (anti-CD38) in both CDC and apoptosis assays, XON27 was able to kill up to 100% of cancer cells without affecting PBMC. Although many therapeutic advances have been made in the field of blood cancers, myeloma remains an incurable disease with a real need for new innovative therapies. XON27 represents a promising and selective immunotherapy which may provide an effective and safe treatment against refractory myeloma."

B Cell Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

FIPO23: A first-in-human trial of XON7, a Glyco-Humanized Polyclonal Antibody (GHpAb)targeting multiple tumor antigens in advanced solid tumors (ESMO 2025) - P1/2 | "Conclusions XON7, a polyclonal antibody targeting several tumor antigens, demonstrates a favorable safety profile and early signs of antitumor activity in heavily pretreated patients with advanced solid tumors. Expansion cohorts will follow."

First-in-human • Metastases • P1 data • Brain Cancer • Colorectal Cancer • Glioblastoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • ANXA2 • CD8 • CKAP4 • DKK1 • SLC3A2

The FIPO23 trial: First-in-human phase I/II study of XON7 in advanced solids tumors. (ASCO 2024) - P1/2 | "As of Feb 3 rd , 2024, 3 pts are enrolled in the first dose cohort and have received XON7 at dose 1,5 mg/kg Q2W for the first 28-days cycle. Conclusions Accrual is ongoing in this first-in-human trial of XON7."

Metastases • P1/2 data • Brain Cancer • Breast Cancer • CNS Tumor • Colon Cancer • Colorectal Cancer • Glioblastoma • Oncology • Solid Tumor • Triple Negative Breast Cancer

FIPO23: FIH XON7 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=255 | Recruiting | Sponsor: Xenothera SAS

Metastases • New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

In vivo anti-tumor effects of XON7 in association with ICIs. (ASCO 2023) - "In vivo data showed a significant increase of response rate and decrease of metastasis when XON7 is associated with anti PD-1. Combination of GH-pAb with ICI could constitute an immunotherapy combination likely to overcome resistance to anti-PD1."

IO biomarker • Preclinical • Hematological Disorders • Hematological Malignancies • Immune Modulation • Lung Cancer • Oncology • Solid Tumor • CD4 • CD8 • GAPDH

Pre-clinical efficacy of the first glyco-humanized oncolytic polyclonal antibody (XON7) in onco-hematology. (ASCO 2023) - "Xenograft mice model: XON7 efficacy was tested in several sub cutaneous xenograft models in NMRI nude mice (n=10 per group) using A549: non-small-cell lung cancer, HCT-116: colon cancer, LnPac: prostate cancer, KMS-12-BM: myeloma, T1301: T cell lymphoma. Immunotherapy with XON7 could be a novel therapeutic approach to fight solid tumors and hematological malignancies. >"

Preclinical • Acute Myelogenous Leukemia • Colon Cancer • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Lung Cancer • Lymphoma • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Osteosarcoma • Prostate Cancer • Sarcoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma

French biotech XENOTHERA publishes its results at the World Cancer Congress in Chicago (ASCO) - from June 2 to 6, 2023 (Businesswire) - "XENOTHERA announces its participation in the ASCO ( American Society of Clinical Oncology ), where the world's cancer specialists gather each year to share data from the latest clinical studies and innovations in cancer....On the occasion of the ASCO, XENOTHERA details the properties of its fourth GH-pAb , XON7, active against solid tumors and in hematology, by publishing two abstracts. The first abstract (N°421432) presents the anti-cancer activity of XON7 on more than 10 solid tumors including non-small cell lung (NSCL), pancreas, liver, colon, prostate, and several lymphomas, in vitro and in vivo. The second abstract (n° 421642) presents the synergy between XON7 and immune checkpoint inhibitors (ICI), in an in vivo model of non-small cell lung cancer....The start of the first clinical study of XON7 is planned before the end of 2023."

New trial • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Liver Cancer • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor